Table 1.
Basic characteristics of the study’s subjects and after weighting.
| Patients Characteristics | Original Cohort | Standardized Difference | Weighted Cohort | Standardized Difference | ||
|---|---|---|---|---|---|---|
| EA | RNU | EA | RNU | |||
| N | 23 | 42 | 23 | 42 | ||
| Age (years) | ||||||
| median IQR |
66.0 (59.0, 77.0) |
69.3 (58.3, 75.6) |
0.06 | 62.0 (30.0, 71.0) |
66.9 (57.7, 74.9) |
−0.26 |
| Male, (%) | 47.83 | 45.24 | 0.05 | 35.26 | 46.41 | −0.23 |
| Biopsy tumor stage, (%) | ||||||
| cTa | 60.87 | 73.81 | 0.28 | 75.49 | 74.06 | −0.03 |
| cT1 | 39.13 | 26.19 | 24.51 | 25.94 | ||
| Biopsy tumor grade, (%) | ||||||
| Low | 26.09 | 40.48 | 0.31 | 51.63 | 39.30 | −0.25 |
| High | 73.91 | 59.52 | 48.37 | 60.70 | ||
| Pathological stage, (%) | ||||||
| pTa | - | 42.86 | - | - | 45.98 | - |
| pT1 | - | 57.14 | - | 54.02 | ||
| Pathological grade, (%) | ||||||
| Low | - | 14.29 | - | - | 18.03 | - |
| High | - | 85.71 | - | 81.97 | ||
| Hydronephrosis, (%) | 30.43 | 78.57 | −1.10 | 53.33 | 69.10 | −0.33 |
| CIS, (%) | ||||||
| 0 | 100.00 | 69.05 | −0.95 | 0.00 | 24.21 | −0.80 |
| 1 | 0.00 | 30.95 | 100.00 | 75.79 | ||
| Tumor Size ≥ 3 cm, (%) | 18.18 a | 35.71 | −0.40 | 43.66 a | 34.47 | 0.19 |
| Pre-operation creatinine median IQR |
1.35 (0.99, 2.34) |
1.02 (0.87, 1.57) |
0.42 |
0.95 (0.53, 1.65) |
0.99 (0.87, 1.56) |
−0.16 |
| Pre-operation eGFR median IQR |
54.5 (27.0, 72.0) |
62.4 (40.6, 82.1) |
−0.45 |
76.0 (38.0, 90.0) |
61.9 (42.3, 82.0) |
0.06 |
| Pre-operative CKD > stage 3, (%) | 52.17 | 42.86 | 0.19 | 34.68 | 42.33 | −0.16 |
| Adjuvant IVCT, (%) | 8.70 | 2.38 | 0.28 | 6.79 | 4.90 | 0.08 |
| Previous/Conc. UC, (%) | 56.52 | 16.67 | 0.91 | 31.82 | 18.58 | 0.31 |
| Tumor site, (%) | ||||||
| Ureter alone | 56.52 | 40.48 | −0.33 | 74.82 | 37.82 | −0.80 |
| Renal pelvis c/w Ureter | 43.48 | 59.52 | 25.18 | 62.18 | ||
| Multifocal, (%) | 73.91 | 100.00 | −0.84 | 43.43 | 100.00 | −1.61 |
a One missing. CIS, carcinoma in situ; eGFR, estimated glomerular filtration rate; CKD, chronic kidney disease; IVCT, intravesical chemotherapy; Conc., concomitant; UC, urothelial carcinoma; c/w, with/without; IQR, interquartile range; EA, endoscopic ablation; RNU, radical nephroureterectomy.